

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231 Pithampur - 454775, Dist. Dhar Madhya Pradesh, India Ph:- 07292-256205 Fax:- 0731-4041435 E mail:- <u>investors@medicaps.com</u> Web site:- <u>www.medicaps.com</u>

Date: 08th February, 2024

MCL/SE/2023-2024

Online filing at: www.listing.bseindia.com

To, **The General Manager** DCS-CRD **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street Fort, Mumbai – 400001(M.H.)

SUBJECT: OUTCOME OF BOARD MEETING HELD ON 08TH FEBRUARY, 2024 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. 08th February, 2024 has inter alia considered and approved the following businesses:

(1) Approval of the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter as well as nine months ended on 31^{st} December, 2023 along with Limited Review Report thereon.

(2) Reconstitution of Audit Committee, Nomination and Remuneration Committee and Stakeholder Relationship Committee w.e.f. 01st April, 2024.

(3) Other routine businesses with the permission of chair.

Further, copy of Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Un-Audited Standalone and Consolidated Financial Results will be uploaded on the Company's website <u>www.medicaps.com</u> and on the website of the Stock Exchange at <u>www.bseindia.com</u>. Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 4.30 P.M.

You are requested to please take on record the same.

Thanking You, Yours Faithfully,

FOR MEDI-CAPS LIMITED

ALOK K GARG MANAGING DIRECTOR DIN: 00274321

Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter and nine months ended 31st December, 2023

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
© Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter and nine month ended 31st December, 2023 of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations")

To, THE BOARD OF DIRECTORS OF MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

- We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the <u>quarter and nine month</u> <u>ended 31st December, 2023</u> attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
- 2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we wave of all significant matters that might be identified in an audit. Accordingly, we denot express an audit opinion.

CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 08.02.2024 Place: Indore UDIN: 24429040BKESEQ6829

For, Rawka & Associates (Chartered Accountants) & ASSO FRN 021606C INDORE (M.P) Venus Rawka (Partner) ed Accou M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435 Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231 UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2023

(Amount in Lacs except EPS)

		Standalo				th Ended	Year Ended	
			Quarter Ende		the second se	Nine Month Ended		
				Corresponding	Year to date	Year to date	Previous Year	
1.1		Ended	Month Ended	03 Month	figure for	figure for	Ended 31.03.2023	
		31.12.2023	30.09.2023	Ended in the	current period	previous year		
5.N.	Particulars			previous year	ended	ended		
	그 것 같은 것 같은 것 같은 것이 없다.			31.12.2022	31.12.2023	31.12.2022		
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I Rev	venue from Operation					0.00		
	Net sales	298.09	210.64	and the second se	508.73	0.00	0.	
	Other operating income	6.65	2.46		10.88 519.61	3.92	10.	
	venue from Operation	304.74	213.10 0.00	0.09	1.04	61.87	64.	
	al income (I+II)	304.98	213.10	1.36	520.65	65.79	74.	
	benses	004.70						
	Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.	
	Purchase of stock in trade	0.00	0.00	0.00			0.	
	Changes in inventories of finished goods,	0.51	0.34	0.00	0.84	0.00	0.	
V	work-in-progress and stock-in-trade							
d) E	Employee benefits expense	28.86		6.03		17.56		
e) F	Finance costs	0.00		0.00		0.00	and the second sec	
	Depreciation and amortisation expense	4.00			12.01	6.92	and the second	
	Power Cost	0.09		0.19		0.19		
	Freight Exp.	0.00	a company of the second s	and the second day is a second day of the second	and a second s	0.00		
	Other expenses	57.91	9.77	2.89		12.54	49	
	tal Expenses (IV)	91.37	19.87	11.42	152.04	57.21	49	
	ofit/(Loss) before exceptional item & tax	312 /1	193.23	-10.06	368.61	28.58	25	
	(-IV)	213.61 0.00				0.00		
	ceptional items	213.61				28.58		
	ofit/ (Loss) before tax (V-VI)	213.01	193.23	-10.00	500.01	20100		
	c expense Current Tax	45.00	0.00	0.00	45.00	0.00	0	
		45.00	0.00					
	Earlier year (excess)/Short provision for tax	0.00	0.00	0.00	0.00	0.00	0	
	tten back ·	0.00	and the second s			0.00		
	Deferred Tax tal Tax Expenses	45.00				0.00	-0	
	t movement in regulatory deferral account		1	1				
	ances related to profit or loss and the		Section 2		Section and the second	State State State	1.	
	ated deferred tax movement	0.00	0.00	0.00	0.00	0.00) (
X Pro	ofit (Loss) for the period from continuing							
ope	erations (VII-VIII)	168.61						
XI Pro	ofit/(loss) from discontinued operations	0.00			and the second s			
	x expense of discontinued operations	0.00						
III Pro	ofit/(loss) from Discontinued operations	0.00	0.00	-3.98	0,00	-9,71	-11	
(aft	ter tax) (XI-XII)							
	ntures accounted for using equity			0.00	0,00	0.00		
KIV me		0.00						
KV Pro	ofit/(loss) for the period (X+XIII)	168.61	193.23	-14.04	523.01	15.07		
(VI Oth	her comprehensive income (i) items that will not be reclassified to		-					
(a)	(1) Items that will not be reclassified to statement of profit & loss	51.38	3 39.7	19.25	5 121.31	-31.32	-32	
	(ii) Income tax on items that will not to							
	be reclassified to statement of P& L	0.00	0.0	0.00	0.00	0.00) (
(b)	(i) items that will be reclassified to							
	statement of profit & loss	0.00	0.0	0.00	0.00	0.00) (
	(ii) Income tax on items that will be							
	reclassified to statement of P& L	0.00						
Ot	her comprehensive income :	51.3	8 39.7	1 19.2:	5 121.3	-31.32	-3	
VII Tot	tal Comprehensive Income for the period							
	V+XVI) (Comprising Profit (Loss) and			4	1 444.92	-12.4	5 -1	
	her Comprehensive Income for the period)	219.9	232.9	4 5.2	444.9	-12.43	-1	
VIII Pro	ofit or Loss Attributable to							
	ofit or Loss Attributable to owners of	0.00	0.0	0.0	0.0	0.0	0	
	rents	0.0	0.0	0.0	0.01	0.0		
	ofit or Loss Attributable to non-Controlling	0.0	0.0	0 0.0	0.0	0.0	0	
	terest	0.0	0.0	0.0	0.01	0.0		
	tal Comprehensive Income for the period	1 Januaria				The second second		
AIA Att	tributable to table for the period		1000					
10	tributable to owners of Parents	0.0	0.0	0.0	0.0	0.0	0	
All	the period	0.0	0.0					
	tributable to non-Controlling Interest	0.0	0.0	0.0	0.0	0.0	0	

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	0.00	4863.75
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	1.35	1.55	-0.08	2.60	0.23	0.21
	b) Diluted (Rs.)	1.35	1.55	-0.08	2.60	0.23	0.21
XXII	Earnings per equity share (for discontinued						
-	a) Basic (Rs.)	0.00	0.00	-0.03	0.00	-0.08	-0.09
-	b) Diluted (Rs.)	0.00	0.00	-0.03	0.00	-0.08	-0.09
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	1.35	1.55	-0.11	2.60	0.15	0.12
	b) Diluted (Rs.)	1.35	1.55	-0.11	2.60	0.15	0.12

DATE: 08.02.2024 PLACE: INDORE

For and on behalf of board of directors of REDI-CAPS LIMITED 6 ALOK K GARC MANAGING DIRECTOR DIN: 00274321

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS 412, Arcade Silver 56, 1, New Palasia, Indore - 1 To Off. : 2541132, Mobile : 9039080380 E-mail : rawkaassociates@gmail.com,.cprawka@gmail.com

1. 4

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Consolidated Unaudited Financial Results for the quarter and nine month ended 31st December, 2023 of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations")

To, THE BOARD OF DIRECTORS OF MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

- 1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary Medgel Private Limited (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and nine month ended December 31, 2023, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.
- 2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting management and applying analytical and other review procedures. A review is substantially less scope conducted in accordance with Standards on Auditing specified under Specified 43610) of the Companies Act, 2013 and consequently does not enable us to obtain assumine that we would ered Accou

become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary Medgel Private Limited.

CONCLUSION

- **5.** Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim consolidated financial results reflect a total income of Rs.707.03Lakhs, total net loss after tax of Rs. (16.42) Lakhs and total comprehensive income of Rs. 120.39 Lakhs for the quarter ended December 31, 2023 as considered in the consolidated financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 08.02.2024 Place: Indore UDIN: 24429040BKESER2668 For, Rawka & Associates (Chartered Accountants) FRN 021606C

MEDI-CAPS LIMITED REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435 Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2023 (Amount in Lacs except EPS)

			Outertan Ender		nsolidated Nine Month Ended		Year Ended	
S.N.	Particulars	03 Month Ended 31.12.2023	Quarter Ended Preceeding 03 Month Ended 30.09.2023	Corresponding 03 Month Ended in the previous year		Year to date figure for previous year ended	Previous Year Ended 31.03.2023	
		(Unaudited)	(Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	(Audited)	
I	Revenue from Operation	(Onaudited)	(Chaudated)	(enduried)				
1	(a) Net sales	692.38	598.50	1093.33		3839.38	4857.75	
	(b) Other operating income	14.65			33.09	40.80		
	Revenue from Operation	707.03		a provide the second state of the second state	a second s		A CONTRACT OF PROPERTY OF A CONTRACT OF A CONT	
Ш	Other Income	9.07	7.40			136.50 4016.68		
III	Total income (I+II)	716.10	610.28	1120.77	1970.82	4010.00	5077,42	
IV	Expenses a) Cost of material consumed	247.64	126.31	411.23	643.99	1720.43	2205.25	
	b) Purchase of stock in trade	0.00						
	c) Changes in inventories of finished goods,	-36,50			the same of the same state of	196.44	85.21	
	work-in-progress and stock-in-trade							
	d) Employee benefits expense	146.84				547.40	and the second s	
	e) Finance costs	0.00				and the second sec		
	f) Depreciation and amortisation expense	45.27				152.26		
	g) Power Cost	32.78			110.98 94.74			
	h) Freight Exp.	57.86			and the second s			
	i) Other expenses	681.90		and the second sec				
V	Total Expenses (IV) Profit/(Loss) before exceptional item & tax	001.50						
Y	(III-IV)	34.14	11.61	133.80	-65.71	412.65	492,07	
VI	Exceptional items	0.00	0.00	0.00	0,00	0.00		
VII	Profit/ (Loss) before tax (V-VI)	34.14	11.61	133.80	-65.71	412.65	492.07	
	Tax expense						100.00	
	1) Current Tax	45.00	0.00	80.00	45.00	80.00	122.00	
	2) Earlier year (excess)/Short provision for tax					102.50	183.5	
	written back	5.56		and the second				
	3) Deferred Tax	0.00						
	Total Tax Expenses	50.50	0.00	203.50	30,30	200.00	000.1	
	Net movement in regulatory deferral account							
IX	balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00	
	deferred tax movement							
X	Profit (Loss) for the period from continuing							
	operations (VII-VIII)	-16,42			and the second			
XI	Profit/(loss) from discontinued operations	0.00		and an and the second data and	the second se			
XII	Tax expense of discontinued operations	0.00						
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.0	0.00	-3.98	0.00	-9.7		
	Share of profit (loss) of associates and joint							
XIV	ventures accounted for using equity method	0.0	0.0					
XV	Profit/(loss) for the period (X+XIII)	-16.4	2 11.6	-133.70	-116.27	139.3	7 175.5	
XVI	Other comprehensive income							
	(a) (i) items that will not be reclassified to	1260	1 110.4	3 53.13	5 365.00	31.7	8 55.9	
	statement of profit & loss	136.8	1 118.43	5 55.1.	505.00	31.11		
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.0	0.0	0.00	0.00	0.0	0.0	
	be reclassified to statement of P& L	0.0	0.0	0.0.	×			
	(b) (i) items that will be reclassified to							
	statement of profit & loss	0.0	0.0	0.0	0.00	0.0	0.0	
	(ii) Income tax on items that will be							
	reclassified to statement of P& L	0.0	0.0	0.01	and the second	and the second sec		
	Other comprehensive income :	136,8	1 118.4	3 53.1	5 365.0	5 31.7	8 55.9	
XVI	I Total Comprehensive Income for the period						-	
	(XV+XVI) (Comprising Profit (Loss) and	100.0	120.0	4 -80.6	0 248.7	9 171.1	4 231.5	
	Other Comprehensive Income for the period)	120.3	9 130.0		240.7			
XVII	Profit or Loss Attributable to	-16.4	2 11.6	1 -133.7	6 -116.2	7 139.3	7 175.5	
	Profit or Loss Attributable to owners of Parents Profit or Loss Attributable to non-Controlling	-10.4	11.0					
	Interest	0.0	0 0.0	0.0	0.0	0.0	0.0	
	Total Comprehensive Income for the period							
XIX	Attributable to				and the second se			
XIX	Attributable to Total Comprehensive Income for the period							
XIX	Attributable to Total Comprehensive Income for the period Attributable to owners of Parents Total Comprehensive Income for the period	120.3	9 130.0	4 -80.6	0 248.7	9 171.1	4 231.5	

			1017.00	1247.00	1247.00	1247.00
in the second of the company	1247.00	1247.00	1247.00		0.00	10610.14
XX Paid-up equity share capital of the company	0.00	0.00	0.00	0.00	0.00	
XXI Reserve Excluding Revaluation Reserve	0.00					
XXII Earnings per equity share (for continuing						
operation)	0.12	0.09	-1.04	-0.93	1.20	1.50
a) Basic (Rs.)	-0.13		-1.04	-0.93	1.20	1.50
b) Diluted (Rs.)	-0.13	0.09	-1.04			
Earnings per equity share (for discontinued						
					-0.08	-0.09
operation)	0.00	0.00	-0.03	0.00		-0.09
a) Basic (Rs.)	- 0.00	0.00	-0.03	0.00	-0.08	-0.03
b) Diluted (Rs.)	0.00	0.00				
XXIV Earnings per equity share (for discontinued						
and continuing operation)			-1.07	-0.93	1.12	1.4
	-0.13	0.09		-0.93	112	1.4
a) Basic (Rs.)	-0.13	0.09	-1.07	-0.93	,	
b) Diluted (Rs.)						

DATE: 08.02.2024 PLACE: INDORE For and on behalf of board of directors of MRDI-CAPS LIMITED

2. ALOK K GARG

MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231 NSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2023 (Amount in Lakhs)

			Quarter En	ded	Nine Mo	Year Ended	
5.No.	Segment Revenue	03 Month Ended 31.12.2023	Preceeding 03 Month Ended 30.09.2023	Corresponding	Year to date figure for current period ended 31.12.2023	Year to date figure for previous year ended 31.12.2022	Previous Year Ended 31.03.2023 Audited
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Auditeu
1	Segment Revenue			1110.41	1450.17	3950.89	5022.83
1	Pharma Division	411.12					
	Real Estate Division	304.98					
	Other	0.00					
	Net Sale/Income From Operations	716.10	610.28	1120.77	1970.02		
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest	E.			-434,3	384.2	466,66
	Pharma Division	-179.47				-	
	Real Estate Division	213.61					
	Other	0.00	0.0	0.0	0.0	0.0	<u> </u>
	Culti				-65.7	412.8	0 492.23
	Total	34.1	4 11.6	1 133.8	2 -05.7	412.0	
	Total					0.0	0.00
	Interest Income	0.0				0	
	Interest Expenses	0.0	0.0			~	
	Other Unallocable Expenditure net off	0.0	0.0				
	Unallocable Income	0.0	0.0	0.0			
	Profit Before Tax	34.1	4 11.6	0 133.8	-65.7	412.0	492.0
2	Capital Employed						
3	Segment Assets (A)					78 12390.3	12434.1:
	Pharma Division	5876.7	6175.6				
	Real Estate Division	6667.2	6391.2				
	Other	0.0	0.0				
	Total (A)	12543.	98 12566.	12557.	10 12543.	98 12557.	
	Segment Liabilities (B)				36 326	53 760.	36 741.5
	Pharma Division	326.			<u>30</u> 00 111.	55	0.0 0.0
	Real Estate Division	111.		57			0.0 0.0
	Other	0.	00	00	00		.36 741.5
	Total (B)	438.	06 581.	38 760.	.30 400.		
4	Total Capital Employed (Segment Assets-Segment						95 11692.0
4	Liabilities)	5550	25 5649	.83 11629			
	Pharma Division	6555		.70 166			
-	Real Estate Division				.00 0	.00 0	.00 0.0
	Other Total Capital Employed (Segment Assets-Segment					ehalf of board of	

Liabilities) DATE: 08.02.2024

PLACE: INDORE

For and on behalf of board of MIDI-CAPS LIMITED

ALOKK GARG

MANAGING DIRECTOR DIN: 00274321

NOTES:

- The above standalone and consolidated unaudited financial results for the Quarter and nine month ended December 31, 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 08, 2024. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
- 4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
- 5. During this quarter the Company has generated the revenue of Rs. 298.09 Lacs from sale/booking of shops.
- 6. The consolidated profit decreased due to lower subsidiary revenue caused by African currency pressure from higher US interest rates and a USFDA warning letter leading to decreased export awaiting a re-audit, with no specified timeline.
- 7. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 8. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors

DATE : 08/02/2024 PLACE: INDORE For and on behalf of the Board of directors of MEDI-CAPS LIMATED

(, 1[°] OK K GARG

MANAGING DIRECTOR DIN: 00274321